VIP (6-28) (human, rat, porcine, bovine)VIP receptor antagonist CAS# 69698-54-0 |
- Daptomycin
Catalog No.:BCC1057
CAS No.:103060-53-3
- Nelarabine
Catalog No.:BCC1072
CAS No.:121032-29-9
- Gemcitabine HCl
Catalog No.:BCC1076
CAS No.:122111-03-9
- Clofarabine
Catalog No.:BCC1078
CAS No.:123318-82-1
- Ifosfamide
Catalog No.:BCC1164
CAS No.:3778-73-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 69698-54-0 | SDF | Download SDF |
| PubChem ID | 90488723 | Appearance | Powder |
| Formula | C126H207N37O34S | M.Wt | 2816.31 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Vasoactive Intestinal Peptide (6-28) | ||
| Solubility | Soluble to 1 mg/ml in water | ||
| Sequence | FTDNYTRLRKQMAVKKYLNSILN (Modifications: Asn-23 = C-terminal amide) | ||
| SMILES | CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)N)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC3=CC=CC=C3)N | ||
| Standard InChIKey | BVEZAVADHLXCKB-KDQGBBDSSA-N | ||
| Standard InChI | InChI=1S/C126H207N37O34S/c1-15-66(10)99(122(195)157-86(53-64(6)7)113(186)150-83(102(135)175)57-94(132)170)161-120(193)92(61-164)159-117(190)90(59-96(134)172)155-114(187)85(52-63(4)5)152-115(188)87(55-71-34-38-73(167)39-35-71)153-109(182)77(30-20-23-46-128)144-107(180)78(31-21-24-47-129)148-121(194)98(65(8)9)160-103(176)67(11)142-105(178)82(44-50-198-14)147-111(184)81(42-43-93(131)169)146-106(179)76(29-19-22-45-127)143-108(181)79(32-25-48-140-125(136)137)145-112(185)84(51-62(2)3)151-110(183)80(33-26-49-141-126(138)139)149-123(196)101(69(13)166)163-119(192)88(56-72-36-40-74(168)41-37-72)154-116(189)89(58-95(133)171)156-118(191)91(60-97(173)174)158-124(197)100(68(12)165)162-104(177)75(130)54-70-27-17-16-18-28-70/h16-18,27-28,34-41,62-69,75-92,98-101,164-168H,15,19-26,29-33,42-61,127-130H2,1-14H3,(H2,131,169)(H2,132,170)(H2,133,171)(H2,134,172)(H2,135,175)(H,142,178)(H,143,181)(H,144,180)(H,145,185)(H,146,179)(H,147,184)(H,148,194)(H,149,196)(H,150,186)(H,151,183)(H,152,188)(H,153,182)(H,154,189)(H,155,187)(H,156,191)(H,157,195)(H,158,197)(H,159,190)(H,160,176)(H,161,193)(H,162,177)(H,163,192)(H,173,174)(H4,136,137,140)(H4,138,139,141)/t66-,67-,68+,69+,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,98-,99-,100-,101-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | VIP receptor antagonist. |
VIP (6-28) (human, rat, porcine, bovine) Dilution Calculator
VIP (6-28) (human, rat, porcine, bovine) Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
VIP(6-28)(human, rat, porcine, bovine) is an effective antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) on cAMP. Sequence: Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn.
In Vitro:VIP(6-28) is an effective VIP antagonist in the superior cervical ganglion (SCG) , and results obtained using this analog indicate that endogenous VIP can participate in a positive feedback loop in injured sympathetic neurons in which it enhances its own expression. VIP(6-28), when added to short-term cultures of adult SCG at a concentration of 10, 30, or 100 μM, reduces the increase in cAMP levels produced by stimulation with 10 μM VIP by 52, 64, or 81%, respectively. At any of these concentrations tested, VIP(6-28) by itself does not alter cAMP levels. In contrast to its ability to reduce the VIP-stimulated elevation in cAMP levels by 64%, the addition of 30 μM VIP(6-28) to culture medium does not significantly alter cAMP levels measured after stimulation of adult ganglia with either isoproterenol or forskolin (10 μM each). Similar results on the ability of VIP(6-28) to block VIP-stimulated increases in cAMP levels are obtained in neuron-enriched and in non-neuronal cell-enriched dissociated cultures[1].
References:
[1]. Mohney RP, et al. Vasoactive intestinal peptide enhances its own expression in sympathetic neurons after injury. J Neurosci. 1998 Jul 15;18(14):5285-93.
- 2,5-Dimethylchroman-4-one
Catalog No.:BCN7200
CAS No.:69687-87-2
- Oleaside A
Catalog No.:BCN6772
CAS No.:69686-84-6
- Mepiroxol
Catalog No.:BCC3810
CAS No.:6968-72-5
- (Z-Cys-OH)2
Catalog No.:BCC2917
CAS No.:6968-11-2
- 6-Aminoindazole
Catalog No.:BCC8762
CAS No.:6967-12-0
- Tanshinone IIA-sulfonic sodium
Catalog No.:BCN2541
CAS No.:69659-80-9
- Didanosine
Catalog No.:BCC3763
CAS No.:69655-05-6
- Trichloro-1,4-dimethoxybenzene
Catalog No.:BCN3494
CAS No.:69653-71-0
- Hesperetin 5-O-glucoside
Catalog No.:BCN3934
CAS No.:69651-80-5
- 5'-Methoxynobiletin
Catalog No.:BCN8031
CAS No.:6965-36-2
- NSC 66811
Catalog No.:BCC2255
CAS No.:6964-62-1
- Pd-C-II
Catalog No.:BCN4599
CAS No.:
- DCB
Catalog No.:BCC7212
CAS No.:6971-97-7
- 6-Amino-1-methyl-5-nitrosouracil
Catalog No.:BCC8756
CAS No.:6972-78-7
- Silvestrol
Catalog No.:BCC1948
CAS No.:697235-38-4
- CRSP-1
Catalog No.:BCC6043
CAS No.:697327-12-1
- BIS-TRIS
Catalog No.:BCC8028
CAS No.:6976-37-0
- W-9 hydrochloride
Catalog No.:BCC6623
CAS No.:69762-85-2
- 4-(3,4-Dimethoxyphenyl)-3-buten-1-ol
Catalog No.:BCN4258
CAS No.:69768-97-4
- Antibiotic BU 2313A
Catalog No.:BCN1846
CAS No.:69774-86-3
- Elvitegravir (GS-9137)
Catalog No.:BCC2134
CAS No.:697761-98-1
- UAMC 00039 dihydrochloride
Catalog No.:BCC6340
CAS No.:697797-51-6
- Swertiajaponin
Catalog No.:BCN2791
CAS No.:6980-25-2
- 2,7-Dihydroxy-2H-1,4-benzoxazin-3(4H)-one
Catalog No.:BCN1374
CAS No.:69804-59-7
An evaluation of the efficacy of vasoactive intestinal polypeptide antagonists in vivo in the anaesthetized dog.[Pubmed:12393943]
Pharmacology. 2002 Dec;66(4):206-10.
The effectiveness of competitive peptide vasoactive intestinal polypeptide (VIP) receptor antagonists was evaluated on heart rate in the anaesthetized dog. Two specific antagonists, VIP (6-28) and [D-p-Cl-Phe(6), Leu(17)]-VIP, and a nonspecific antagonist, pituitary adenylate cyclase activating peptide fragment (6-27) (PACAP), were studied. VIP (6-28) and [D-p-Cl-Phe(6), Leu(17)]-VIP (100 microg i.c.) increased the heart rate, whereas PACAP (100 microg i.c.) reduced the baseline heart rate. All three shifted the VIP dose-response curve to the right by two- to threefold for 30 min. In conclusion, PACAP, VIP (6-28), and [D-p-Cl-Phe(6), Leu(17)]-VIP have a direct effect on the heart rate, are equally effective, and the effects last approximately 30 min in vivo.
Vasoactive intestinal peptide enhances its own expression in sympathetic neurons after injury.[Pubmed:9651211]
J Neurosci. 1998 Jul 15;18(14):5285-93.
Neurons in the adult rat superior cervical sympathetic ganglion (SCG) dramatically increase their content of vasoactive intestinal peptide (VIP) and its mRNA after axotomy in vivo and after explantation. Because the VIP gene contains a functional cAMP response element, the effects of cAMP-elevating agents on VIP expression were examined. VIP, forskolin, or isoproterenol increased cAMP accumulation in explanted ganglia. Secretin, a peptide chemically related to VIP, or forskolin increased VIP levels above those seen in ganglia cultured in control medium, whereas treatment with VIP or secretin increased the level of peptide histidine isoleucine (PHI), a peptide coded for by the same mRNA that encodes VIP. VIP or forskolin also increased VIP-PHI mRNA. In contrast, isoproterenol did not alter levels of VIP, PHI, or VIP-PHI mRNA. Although VIP or forskolin increased cAMP levels in both dissociated neurons and in non-neuronal cells, isoproterenol significantly stimulated cAMP accumulation only in the latter. VIP6-28 was an effective antagonist of the actions of exogenous VIP on cAMP and VIP-PHI mRNA in neuron-enriched cultures. When adult SCG explants were cultured in defined medium, endogenous VIP immunoreactivity was released. When VIP6-28 was added to such cultures, it significantly inhibited the increase in VIP-PHI mRNA that normally occurs. These data indicate that VIP, or a closely related molecule, produced by adult neurons after injury can enhance the expression of VIP. Such a mechanism may prolong the period during which VIP is elevated after axonal damage. The possibility is also discussed that, because VIP is present in preganglionic neurons in normal animals, its release during periods of increased sympathetic nerve activity could alter VIP expression in the SCG.
A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists.[Pubmed:7912431]
Peptides. 1994 Jan;15(1):95-100.
The ability to assess the importance of VIP in different physiological processes is limited by the lack of specific potent antagonists. In the present study, we have adopted two different approaches used successfully with other peptides in an attempt to identify new VIP receptor antagonists. One involves the formation of pseudopeptides by insertion of reduced peptide bonds in the NH2-terminus from position 2 to 8 of VIP. The other methodology involves the formation of a COOH-terminal chimeric analogue by combining VIP(6-28) and PACAP(28-38). The ability of each of these peptides to function as an antagonist was compared with reported VIP antagonists. All of the peptides inhibited [125I]VIP binding to VIP receptors on guinea pig pancreatic acini. For the pseudopeptides the affinities were: [psi 3-4]VIP (0.2 microM) = 4 x [psi 4-5]VIP = 8 x [psi 8-9]VIP = 14 x [psi 6-7]VIP, [psi 2-3]VIP = 25 x [psi 5-6]VIP. Each nonpseudopeptide analogue also inhibited VIP binding with relative potencies of VIP(6-28)-PACAP(28-38) (1 microM) = 2.5 x [4-Cl-D-Phe6,Leu17]VIP, VIP(10-28), neurotensin(6-11)-VIP(7-28) = 6 x [Ac-Tyr1,D-Phe2]GRF. All pseudopeptides were agonists with relative potencies: [psi 3-4]VIP > [psi 6-7], [psi 4-5]VIP > [psi 5-6] > [psi 8- 9]VIP > [psi 2-3]VIP. The reported VIP receptor antagonist, neurotensin(6-11)-VIP(7-28), was also an agonist.(ABSTRACT TRUNCATED AT 250 WORDS)
